SCHEMBL4267172

SCHEMBL4267172

Cc1ccc2c(c1)C1(NC(=O)NC1=O)C(=O)N2Cc1ccccc1C(F)(F)F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM5 P08912 1/20 0.42
C5AR1 P21730 1/20 0.41
ALDH1A1 P00352 4/20 0.39
TSHR P16473 2/20 0.39
EDNRB P24530 1/20 0.38
EDNRA P25101 1/20 0.38
PTGDR2 Q9Y5Y4 1/20 0.38
TDP1 Q9NUW8 3/20 0.37
KDM4E B2RXH2 2/20 0.37
ATM Q13315 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 1/20 0.37
KMT2A Q03164 1/20 0.37
GAA P10253 2/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2C19 P33261 1/20 0.36
ADAMTS5 Q9UNA0 1/20 0.36
MAPT P10636 3/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4256761 0.89 CHRM5 (0.53) CHRM5C5AR1PTGDR2CA12CA1
SCHEMBL4254919 0.84 TSHR (0.39) ALDH1A1TSHRPTGDR2KMT2AADAMTS5
SCHEMBL4257022 0.84 TP53 (0.39) ALDH1A1TSHRPTGDR2KMT2AADAMTS5
SCHEMBL4977919 0.82 KMT2A (0.40) CHRM5C5AR1ALDH1A1EDNRBEDNRA
SCHEMBL4262087 0.82 ADAMTS5 (0.41) ALDH1A1TSHRPTGDR2CYP2C9ADAMTS5
SCHEMBL4266563 0.82 HSP90AA1 (0.37) PTGDR2MAPTTP53CA1CA9
SCHEMBL4258212 0.82 AR (0.53) ALDH1A1PTGDR2ADAMTS5MAPTTP53
SCHEMBL4259885 0.82 ADAMTS5 (0.52) ALDH1A1TDP1NPSR1MEN1KMT2A
SCHEMBL4260823 0.81 HSP90AA1 (0.52) CHRM5ALDH1A1NPSR1ADAMTS5MAPT
SCHEMBL4262078 0.81 HSP90AA1 (0.39) ALDH1A1PTGDR2NPSR1ADAMTS5MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 US claimed
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 ASTRAZENECA AB (SE) 2009-07-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176851-A1 Use of Spiro [Imidazolidine-4, 3' -Indole] 2, 2', 5' (1H) Triones for Treatment of Conditions Associated with Vanilloid Receptor 1 TRPV1, TRPV2, TRPV3 CHRM5 507/4885C5AR1 1499/4885ALDH1A1 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.